Melanoma clonal heterogeneity leads to secondary resistance after adoptive cell therapy with tumor-infiltrating lymphocytes

Skin Cancer

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Immunooncol Technol

König D, Kasenda B, Sandholzer M, Chirindel A, Zingg A, Ritschard R, Thut H, Glatz K, Kappos EA, Schaefer D, Kettelhack C, Passweg J, Baur K, Holbro A, Buser A, Lardinois D, Jeker LT, Khanna N, Stenner F, Matter MS, Rodrigues Mantuano N, Binder M, Zippelius A, Läubli H

doi: 10.1016/j.iotech.2024.100728

Skin Cancer

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma

Sci Immunol

Barras D, Ghisoni E, Chiffelle J, Orcurto A, Dagher J, Fahr N, Benedetti F, Crespo I, Grimm AJ, Morotti M, Zimmermann S, Duran R, Imbimbo M, de Olza MO, Navarro B, Homicsko K, Bobisse S, Labes D, Tsourti Z, Andriakopoulou C, Herrera F, Pétremand R, Dummer R, Berthod G, Kraemer AI, Huber F, Thevenet J, Bassani-Sternberg M, Schaefer N, Prior JO, Matter M, Aedo V, Dromain C, Corria-Osorio J, Tissot S, Kandalaft LE, Gottardo R, Pittet M, Sempoux C, Michielin O, Dafni U, Trueb L, Harari A, Laniti DD, Coukos G

doi: 10.1126/sciimmunol.adg7995

Skin Cancer

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Immunity

Chiffelle J, Barras D, Pétremand R, Orcurto A, Bobisse S, Arnaud M, Auger A, Rodrigo BN, Ghisoni E, Sauvage C, Saugy D, Michel A, Murgues B, Fahr N, Imbimbo M, Ochoa de Olza M, Latifyan S, Crespo I, Benedetti F, Genolet R, Queiroz L, Schmidt J, Homicsko K, Zimmermann S, Michielin O, Bassani-Sternberg M, Kandalaft LE, Dafni U, Corria-Osorio J, Trueb L, Dangaj Laniti D, Harari A, Coukos G

doi: 10.1016/j.immuni.2024.08.014

Lung, Respiratory and Thoracic Cancer

Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma

Lung Cancer

Szentkereszty M, Ladányi A, Gálffy G, Tóvári J, Losonczy G

doi: 10.1016/j.lungcan.2024.107824

Leukemia

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Br J Haematol

Perutelli F, Boccellato E, Montalbano MC, Catania G, Deodato M, Frustaci AM, Innocenti I, Moia R, Quaglia FM, Quaresmini G, Rivela P, Gaidano G, Krampera M, Laurenti L, Rambaldi A, Bruno B, Vitale C, Coscia M

doi: 10.1111/bjh.19976

Lymphoma

Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study

Br J Haematol

Barone A, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Barbui AM, Farina M, Brunello L, Di Chio MC, Novo M, Musso M, Olivieri J, Trotta GE, Dodero A, Aiello A, Corradini P

doi: 10.1111/bjh.19590

Lymphoma

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Haematologica

Benjamini O, Fried S, Shouval R, Flynn JR, Beyar-Katz O, Leslie LA, Zucherman T, Yerushalmi R, Shem-Tov N, Palomba ML, Danylesko I, Sdayoor I, Malka H, Itzhaki O, Suh H, Devlin SM, Marcus R, Dahi PB, Jacoby E, Shah GL, Sauter CS, Ip A, Perales MA, Nagler A, Shimoni A, Scordo M, Avigdor A

doi: 10.3324/haematol.2023.284664

Lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Br J Haematol

de la Iglesia-San Sebastián I, López-Esteban M, Bastos-Oreiro M, Fernández de Córdoba-Oñate S, Gutierrez M, Carbonell D, Bailén R, Gómez-Centurión I, Fernández-Caldas P, Castilla L, Anguita J, Kwon M, García-Sanz R, Buño I, Martínez-Laperche C

doi: 10.1111/bjh.19916

Skin Cancer

Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB

Eur J Cancer

Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, Wolfsperger F, Meraz-Torres F, Chatziioannou E, Martus P, Flatz L, Garbe C, Leiter U

doi: 10.1016/j.ejca.2024.113912

Related content

Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8(+) T-myeloid cell networks in melanoma

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma

Density of tumor-infiltrating NK and Treg cells is associated with 5 years progression-free and overall survival in resected lung adenocarcinoma

Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation

Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study

Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma

Chimeric antigen receptor copies in cell-free DNA predict relapse in aggressive B-cell lymphoma patients treated with CAR T-cell therapy

Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB